Godrej Industries Limited (GODREJIND) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Godrej Industries is the holding company of the Godrej group, with direct Chemicals, Estate Management and Finance & Investments businesses and stakes in Godrej Consumer Products, Godrej Properties, Godrej Agrovet and Godrej Capital. This quarter's print will speak to whether Chemicals can hold its Q1 margin rebound against palm-oil feedstock and US tariff pressure, and whether Godrej Properties' bookings are tracking its over Rs. 39,000 Cr FY27 guidance.
| Results date | November 13, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 6,360 Cr (Total Income, Q1 FY27, +11% YoY) |
| Previous quarter PAT | Rs. 284 Cr (Q1 FY27, -19% YoY) |
| Previous quarter EBITDA margin | 25.31% (PBDIT/Total Income, Q1 FY27) |
| Market cap | Rs. 32,197.91 Cr |
| CMP | Rs. 955.85 |
Godrej Industries Limited Q2 Results Date and Time
Board meets Nov 13, 2026 for Q2/H1 FY27 (Sep 30, 2026) results.
What to expect from Godrej Industries Limited's Q2 FY27 results
The quarter is a checkpoint on two fronts: whether Godrej Properties' Q2 bookings keep pace with the over Rs. 39,000 Cr FY27 guidance (22% achieved after Q1's Rs. 8,651 Cr, +22% YoY), and whether the Chemicals division sustains its Q1 FY27 PBIT margin of 13.69% against palm-oil feedstock and tariff pressure.
The residential demand backdrop improved through the quarter — MMR sales rose 11% QoQ in Q3 2026 after a 13% QoQ dip, and pan-India sales turned positive YoY at +3% with launches up 18% — though top-7-city inventory overhang of about 19 months is the counterpoint.
On costs, palm oil prices were up roughly 21% YoY through the quarter and Brent breached $100 in September, while the rupee fell past 95/USD — the mix the company itself flags as raising input and financing costs; the September 24 duty cut on crude palm oil and the oil pull-back to about $98 by early November arrived only in the quarter's final weeks.
The finance-cost line is a further drag: consolidated interest has risen every quarter to Rs. 745 Cr in Q1 FY27 (+29.30% YoY), and the Rs. 750 Cr NCD at 8.50% allotted September 18 adds to the borrowings. The first biosurfactant launch was targeted for Q2 FY27 — the very quarter being reported — and the Rs. 750 Cr Chemicals capex/M&A program by 2028 was stated as on track. This will also be the first results under Executive Chairperson Pirojsha Godrej, whose five-year term began August 14, 2026.
Key Things To Watch
Guidance scorecard: Tracked goals from management's stated guidance, and where each stands.
- Chemicals Rs. 750 Cr capex/M&A — by 2028 — check spend progress ('on track' as of FY26)
- GPL bookings over Rs. 39,000 Cr — FY27 — 22% done after Q1; Q2 FY27 bookings are the key checkpoint
- GPL OCF approximately Rs. 9,000 Cr — FY27 — only Rs. 399 Cr in Q1 (-58% YoY); back-loading risk, and management deferred a definitive FY27 free-cash-flow answer to this call
- GPL ROE 20% — by FY28; GPL deliveries 13.5 mn sq ft — FY27; GPL Haryana Rs. 16,000 Cr — by FY28
- Biosurfactant launch — Q2 FY27 — the target quarter is the one being reported; AHF scale to 15 Tamil Nadu locations — by FY27
Chemicals margin sustainability
- Q1 FY27 PBIT margin of 13.69% (derived) vs 3.63% in Q4 FY26 — watch whether the rebound holds
- Feedstock and tariff commentary: US reciprocal/punitive tariffs have hit US sales, and palm oil prices were up roughly 21% YoY through the quarter
- Whether specialty/biotech mix gains continue — Specialty Chemicals volumes grew 37% in FY26 to about 11% of division turnover
Interest-cost trajectory and NCD deployment
- Consolidated interest rose every quarter — Rs. 584 Cr (Q2 FY26) to Rs. 626 Cr (Q3) to Rs. 684 Cr (Q4) to Rs. 745 Cr (Q1 FY27), +29.30% YoY
- Use of the Rs. 750 Cr NCD proceeds (8.50% coupon, allotted Sep 18, 2026) — business purposes, investments, loan repayment, general corporate purposes
GCPL momentum and GAVL Crop Care recovery
- Whether GCPL's +19% sales growth and +9% underlying volume growth in Q1 FY27 holds
- GAVL Q1 FY27 PAT fell 16.15% YoY (derived) — watch Crop Care (Rs. 349 Cr vs Rs. 403 Cr) recovery; Q1 cattle feed volumes grew about 15% YoY
Standalone loss trend and leadership narrative
- Q1 FY27 standalone loss of Rs. (5.41) Cr, improved from Rs. (29.98) Cr — watch the trend
- First results reported under Executive Chairperson Pirojsha Godrej (term from Aug 14, 2026) — watch for strategic emphasis shifts
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
When will Godrej Properties' revenue bump show up in Godrej Industries' numbers?
GPL MD & CEO Gaurav Pandey has said FY27 will see the revenue bump-up only partially, stating: "I think we would see that major bump up in FY28". FY27 is therefore a year of deliveries building toward a larger FY28 recognition.
Is Godrej Properties confident about FY27 growth?
Management has affirmed strong confidence in sustaining healthy growth across key metrics, including top-line growth and booking value, expecting to grow ahead of the market even if the overall market stagnates. GPL went on to deliver 105% of its FY26 booking guidance.
How sold-out are Godrej Properties' FY28 projects?
Projects contributing to the Rs. 40,000 crores booking value are largely sold out — Aristocrat is 98% sold and Reserve has sold over Rs. 6,000 crores. Bangalore, Hyderabad and Noida were described as performing exceptionally well in Q1 FY27, with core Bombay and Thane strong and Pune improving.
What did Godrej Industries report in Q1 FY27?
Consolidated Total Income rose 11% YoY to Rs. 6,360 Cr, but PBDIT fell 8% to Rs. 1,610 Cr and net profit fell 19% to Rs. 284 Cr, with interest up to Rs. 745 Cr from Rs. 576 Cr. The Chemicals division drove the rebound, with revenue up 31% to Rs. 1,161 Cr and PBIT up 86% to Rs. 159 Cr.
Related
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.